The FDA said it is allowing selected patients with Lou Gehrig's disease to use Iplex, Insmed's treatment for growth-hormone deficiency, as the company awaits the conclusion of a patent-infringement case that put sales on hold. Insmed plans to use part of its "very limited" supply of Iplex to conduct safety trials.

Full Story:

Related Summaries